Skip to main content
SpringerLink
Log in

Mosapride

In Gastrointestinal Disorders

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Mosapride was effective in improving overall symptoms in patients with gastrointestinal disorders, including chronic gastritis, gastro-oesophageal reflux disease and functional dyspepsia.

  • ▴ Mosapride was more effective than teprenone in improving gastric stasis symptoms and gastric pain after 2 weeks of therapy (p < 0.001) in an open-label trial in 1042 patients with functional dyspepsia.

  • ▴ Mosapride was as effective as famotidine and itopride, but more effective than tandospirone, in improving overall or individual symptoms of functional dyspepsia in randomized trials. However, in one randomized, double-blind trial in patients with mild to severe disease, the improvement in overall symptoms of functional dyspepsia did not differ significantly between mosapride or placebo treatment.

  • ▴ Mosapride was well tolerated, with diarrhoea/loose stools, dry mouth, malaise and headache being reported in <5% of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Mizuta Y, Shikuwa S, Isomoto H, et al. Recent insights into digestive motility in functional dyspepsia. J Gastroenterol 2006 Nov;41(11): 1025–40

    Article  PubMed  Google Scholar 

  2. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999 Sep; 45 Suppl. 2: II43–7

    Article  PubMed  Google Scholar 

  3. Grundy D, AL-Chaer ED, Aziz Q, et al. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130(5): 1391–411

    Article  PubMed  CAS  Google Scholar 

  4. Makimoto N, Sukurai-Yamashita Y, Furuichi A, et al. In vivo assessment of acceleration of motor activity associated with acetylcholine release via 5-hydroxytriptamine. Jpn J Pharmacol 2002; 90: 28–35

    Article  PubMed  CAS  Google Scholar 

  5. Carlsson L, Amos GJ, Andersson B, et al. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997 Jul; 282(1): 220–7

    PubMed  CAS  Google Scholar 

  6. Toga T, Kohmura Y, Kawatsu R. The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci 2007 Oct; 105(2): 207–10

    Article  PubMed  CAS  Google Scholar 

  7. Potet F, Bouyssou T, Escande D. Gastrointestinal prokinetic drugs have a different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther 2001; 289(3): 1007–12

    Google Scholar 

  8. Yoshida N, Kato S, Ito T. Mosapride citrate: gastroprokinetic. Drugs Future 1993; 18(6): 513–5

    Google Scholar 

  9. Karasawa T, Yoshida N, Furukawa K, et al. Comparison of gastrokinetic effects of AS-4370, cisapride and BRL 24924. Eur J Pharmacol 1990 Jul 6; 183: 2181

    Article  Google Scholar 

  10. Yoshida N, Omoya H, Furukawa K, et al. Pharmacological studies on mosapride citrate (AS-4370), a gastroprokinetic agent (1): comparison with cisapride and metoclopramide [in Japanese]. Jpn Pharmacol Ther 1993; 21(9): 249–64

    Google Scholar 

  11. Yoshida N, Omoya H, Oka M, et al. AS-4370, a novel gastrokinetic agent free of dopamine D2 receptor antagonist properties. Arch Int Pharmacodyn Ther 1989; 300: 51–67

    PubMed  CAS  Google Scholar 

  12. Yoshida N, Omoya H, Kato S, et al. Pharmaocological effects of the new gastroprokinetic agent mosapride citrate and its metabolite in experimental animals. Arzneimittelforschung 1993; 43(10): 1078–83

    PubMed  CAS  Google Scholar 

  13. Hamelin B, Bredberg E, Röhss K, et al. Effects of mosapride on oesophageal motility in humans [abstract no. A51]. Dig Dis Sci 1996 Sep; 41(9): 1892

    Google Scholar 

  14. Mitsufuji S, Nakao H, Taniguchi J, et al. Effect of mosapride citrate on esophageal motility in healthy subjects and patients with gastroesophageal reflux disease [in Japanese]. Prog Med 2002; 22(3): 801–5

    Google Scholar 

  15. Ruth M, Finizia C, Cange L, et al. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2003 Oct; 15(10): 1115–21

    Article  PubMed  CAS  Google Scholar 

  16. Cho YK, Choi M-G, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40(4): 286–92

    Article  PubMed  CAS  Google Scholar 

  17. Kanaizumi T, Nakano H, Matsui Y, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41(4): 335–7

    Article  PubMed  CAS  Google Scholar 

  18. Suyama T, Tokubayashi F, Omatsu Y, et al. Accelerating effect of AS-4370 (mosapride) on gastric emptying time (double sampling test method) and its clinical efficacy on chronic gastritis accompanied by epigastric symptoms [in Japanese]. Jpn Arch Intern Med 1993; 40(7): 175–83

    Google Scholar 

  19. Wei W, Ge Z-Z, Lu H, et al. Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol 2007 Oct; 22(10): 1605–8

    Article  PubMed  Google Scholar 

  20. Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson’s disease. Parkinsonism Relat Disord 2005; 11(8): 499–502

    Article  PubMed  Google Scholar 

  21. Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61(3): 175–82

    Article  PubMed  CAS  Google Scholar 

  22. Yamada M, Hongo M. Effects of prokinetic agents: comparison between AS4370 and EM523L. Gastroenterol Jpn 1993 Dec; 28(6): 836

    Google Scholar 

  23. Inui A, Yoshikawa T, Nagai R, et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonie motilit in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 313–20

    Article  PubMed  CAS  Google Scholar 

  24. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 anatgonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20(6): 680–6

    Article  PubMed  Google Scholar 

  25. Kojima Y, Fujii H, Katsui R, et al. Enhancement of the intrinsic defecation reflex by mosapride, a 5-HT4 agonist, in chronically lumbosacral denervated guinea pigs. J Smooth Muscle Res 2006; 42(5): 139–47

    Article  PubMed  Google Scholar 

  26. Kojima Y, Nakagawa T, Katsui R, et al. A 5-HT4 agonist, mosapride, enhances intrinsic rectorectal and rectonal reflexes after removal of extrinsic nerves in guinea pigs. Am J Physiol Gastrointest Liver Physiol 2005; 289: G351–60

    Article  PubMed  CAS  Google Scholar 

  27. Ruth M, Hamelin B, Röhss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12(1): 35–40

    Article  PubMed  CAS  Google Scholar 

  28. Itoh H, Nagano T, Takeyama M. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin. Biol Pharm Bull 2001 Sep; 24(9): 1072–5

    Article  PubMed  CAS  Google Scholar 

  29. Hayakawa A, Kawahara K, Ueda Y, et al. Clinical study of AS-4370 in non-ulcer dyspepsia: effects of AS-4370 on upper abdominal symptoms and on hormones [in Japanese]. Rinsho Iyaku 1992; 8(3): 639–45

    Google Scholar 

  30. Kii Y, Ito T. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol 1997 May; 29(5): 670–5

    Article  PubMed  CAS  Google Scholar 

  31. Katoh T, Saitoh H, Ohno N, et al. Drug interaction between mosapride and erythromycin without electrocardiographic changes. Jpn Heart J 2003 Mar; 44(2): 225–34

    Article  PubMed  CAS  Google Scholar 

  32. Horii S, Takeda T, Fujimoto Y, et al. Clinical study on safety of mosapride in combination therapy with psychiatric drugs [in Japanese]. Rinsho Iyaku 2000; 16(2): 153–62

    Google Scholar 

  33. Takeuchi Y, Watanabe H, Imawari M. Mosapride citrate, a serotonin HT4 selective agonist, beneficially affects pharmacokinetics of proton pump inhibitor [abstract no. T1693]. Gastroenterology 2005 Apr; 128 (4 Suppl. 2): A–531

    Google Scholar 

  34. Sakashita M, Yamaguchi T, Miyazaki H, et al. Pharmaco-kinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects. Arzneimittelforschung 1993; 43(8): 867–72

    PubMed  CAS  Google Scholar 

  35. Ogihara T, Higaki J, Azuma J, et al. Pharmacokinetic study of AS-4370 in the elderly: comparison with the young [in Japanese]. Rinsho Iyaku 1994; 10(11): 2489–97

    Google Scholar 

  36. Dainippon Pharmaceutical Co., Ltd. Gasmotin®: mosapride citrate preparation. Prescribing information. Osaka, 2004

  37. Miyoshi A, Yoshida Y, Masamune O, et al. Phase II study of two dosage regimens of AS-4370 tablet: randomised comparison of doses taken before and after meals [in Japanese]. Rinsho Iyaku 1998; 14(6): 1025–36

    Google Scholar 

  38. Misawa T, Okabe H, Chijiiwa Y, et al. Clinical study of AS-4370 on upper abdominal symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(9): 2167–76

    Google Scholar 

  39. Toyota T, Hongo M, Sato M, et al. Clinical evaluation of mosapride citrate (AS-4370) on dyspepsia symptoms in chronic gastritis [in Japanese]. Rinsho Iyaku 1993; 9(8): 1887–95

    Google Scholar 

  40. Miyoshi A, Miwa T, Harasawa S, et al. Dose-finding study of AS-4370 (mosapride citrate) in patients with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1069–90

    Google Scholar 

  41. Miyoshi A, Miwa T, Harasawa S, et al. Clinical evaluation of AS-4370 on epigastric symptoms associated with chronic gastritis [in Japanese]. Rinsho Iyaku 1998; 14(6): 1037–53

    Google Scholar 

  42. Miyoshi A, Miwa T, Harasawa S, et al. Dose finding study of AS-4370 in patients with non-ulcer dyspepsia [in Japanese]. Rinsho Iyaku 1990 Nov; 6: 2295–310

    Google Scholar 

  43. Miyoshi A, Sekiguchi T, Miwa T, et al. Clinical assessment of AS-4370 in the treatment of reflux oesophagitis: dose-comparison study by randomization [in Japanese]. Rinsho Iyaku 1993; 9(6): 1327–41

    Google Scholar 

  44. Hongo M. Initial approach and pharmacotherapy for functional dyspepsia: a large clinical trial in Japan [abstract no. T1247, plus poster]. Gastroenterology 2006 Apr; 130 (4 Suppl. 2): 506

    Google Scholar 

  45. Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002 May; 16(5): 959–67

    Article  PubMed  Google Scholar 

  46. Kinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 37–41

    Article  Google Scholar 

  47. Otaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005 Jun; 21 Suppl. 2: 42–6

    Article  Google Scholar 

  48. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005 Jan 1; 21 Suppl. 2: 32–6

    Article  Google Scholar 

  49. Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004 Dec; 102(12): 735–7, 760

    PubMed  Google Scholar 

  50. Miyoshi A, Sekiguchi T, Harasawa S, et al. Clinical evaluation of mosapride (AS-4370) on gastroesophageal reflux disease: multi-centered double-blind comparative study with cisapride [in Japanese]. Rinsho Iyaku 1998; 14(6): 1055–68

    Google Scholar 

  51. Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus 2004; 17(4): 274–8

    Article  PubMed  CAS  Google Scholar 

  52. Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in ambulatory patients with epigastric digestive tract disorder after gastric surgery by double-blind study [in Japanese]. Rinsho Iyaku 1992; 8(7): 1559–68

    Google Scholar 

  53. Kanaizumi T, Nakano H. Clinical evaluation of long-term administration of mosapride citrate (AS-4370) in postoperative ambulatory patients with epigastric digestive tract disorders [in Japanese]. Rinsho Iyaku 1993; 9(8): 1879–86

    Google Scholar 

  54. Kanaizumi T, Nakano H, Kuriya N. Clinical evaluation of AS-4370 in hospitalized patients with epigastric symptoms after gastric surgery in a double-blind comparative study [in Japanese]. Rinsho Iyaku 1992; 8(12): 2831–40

    Google Scholar 

  55. Odaka T, Suzuki T, Seza A, et al. Serotonin 5-HT4 receptor agonist (mosapride citrate) [in Japanese]. Nippon Rinsho 2006; 64(8): 1491–4

    PubMed  Google Scholar 

  56. Hiyama T, Yoshihara M, Matsuo K, et al. Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2007 Oct; 22(10): 1566–70

    Article  PubMed  Google Scholar 

  57. Oikawa T, Takemoto Y, Haramu K. Postmarketing surveillance of mosapride citrate (Gasmotin®) in patients with non-ulcer dyspepsia on long-term administration [in Japanese]. Rinsho Iyaku 2005; 21(8): 831–7

    Google Scholar 

  58. Ohki R, Takahashi M, Mizuno O, et al. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing Clin Electrophysiol 2001 Jan; 24(1): 119–21

    Article  PubMed  CAS  Google Scholar 

  59. Dainippon Pharmaceutical Co. Ltd. Launch of Gasmotin® in South Korea [media release]. Available from URL: http://www.dainippon-pharm.co.jp [Accessed 2008 Mar 14]

  60. Eisai TMCL. Eisai submits application for gastroprokinetic agent Gasmotin® in Thailand [media release]. Available from URL: http://www.eisai.co.jp [Accessed 2008 Jan 17]

  61. Dainippon Sumitomo Pharma Co. Ltd., Eisai Co.. Dainippon Sumitomo Pharma and Eisai signed licensing agreement for Gasmotin®, a gastroprokinetic agent, for countries in Asia including ASEAN members [online]. Available from URL: http://www.ds-pharma.co.jp [Accessed 2008 Jan 17]

Download references

Acknowledgements

The article was reviewed by: T. Hiyama, Hiroshima University, Higashihiroshima, Japan; Y. Kinoshita, Shimane University School of Medicine, Shimane, Japan; V. Stanghellini, Università degli Studi di Bologna, Bologna, Italy.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ¦ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Monique P. Curran & Dean M. Robinson

  2. Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Monique P. Curran & Dean M. Robinson

Authors
  1. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean M. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monique P. Curran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, M.P., Robinson, D.M. Mosapride. Drugs 68, 981–991 (2008). https://doi.org/10.2165/00003495-200868070-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200868070-00007

Keywords

Search

Navigation